article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
List view / Grid view
Inovio Pharmaceuticals
news
CEPI announces three programmes to develop coronavirus vaccine
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
news
DNA-based Zika vaccine found effective at inducing immune response
A new generation DNA-based Zika vaccine is the first to demonstrate both safety and the ability to elicit an immune response against Zika in humans...
news
Inovio updates clinical strategy for INO-3112 HPV immunotherapy
29 March 2016 | By Victoria White
Inovio has updated its clinical strategy to take its INO-3112 HPV immunotherapy into human studies in combination with selected molecules from MedImmune...
news
Inovio’s dMAb antibody and DNA vaccine provides 100% protection against CHIKV
22 March 2016 | By Victoria White
Inovio’s DNA vaccine and dMAb products show potential to offer immediate and long term protection to large populations from CHIKV infection...
news
Inovio and Wistar team up for DNA-based immunotherapies
16 March 2016 | By Victoria White
Inovio and the Wistar Institute are to research preventive and therapeutic DNA-based immunotherapies for cancers and infectious diseases...
news
Dr David B. Weiner joins Inovio’s Board of Directors
14 March 2016 | By Victoria White
Dr Weiner was co-founder with J. Joseph Kim, Ph.D., Inovio’s CEO, of VGX Pharmaceuticals in 2000; via merger VGX later became Inovio Pharmaceuticals...
news
Inovio’s DNA vaccine for Zika virus induces robust responses
17 February 2016 | By Victoria White
In preclinical studies, Inovio's Zika DNA vaccine resulted in seroconversion, or the development of detectable specific antibodies in the blood...
news
FDA clears first-in-human clinical study for MERS vaccine
19 November 2015 | By Victoria White
GeneOne Life Science and Inovio are co-developing the vaccine and plan to initiate the first human trial of a MERS vaccine before the end of the year...
news
Investigational New Drug Application filed for MERS vaccine
19 October 2015 | By Victoria White
Earlier this year, Inovio’s MERS vaccine induced 100% protection from a live virus challenge in a preclinical study...
news
Inovio receives $24m grant to advance Ebola programme
21 September 2015 | By Victoria White
DARPA is to provide the additional $24 million after Inovio successfully completed certain preclinical and clinical development milestones relating to the Ebola treatment programme...
news
Inovio’s DNA-based monoclonal antibody (dMAb) protects against dengue
30 July 2015 | By Victoria White
Inovio’s DNA-based monoclonal antibody (dMAb) targeting dengue virus provided protection against a lethal dengue virus challenge in mice...
news
Inovio partners with GeneOne Life Science for MERS vaccine clinical development
3 June 2015 | By Victoria White
Inovio has said it will advance its DNA vaccine for MERS into a Phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science...